224 related articles for article (PubMed ID: 24789443)
21. Racial variation in breast cancer treatment among Department of Defense beneficiaries.
Enewold L; Zhou J; McGlynn KA; Anderson WF; Shriver CD; Potter JF; Zahm SH; Zhu K
Cancer; 2012 Feb; 118(3):812-20. PubMed ID: 21766298
[TBL] [Abstract][Full Text] [Related]
22. Racial and ethnic differences in adjuvant hormonal therapy use.
Livaudais JC; Li C; John EM; Terry MB; Daly M; Buys SS; Habel L; Thompson B; Yanez ND; Coronado GD
J Womens Health (Larchmt); 2012 Sep; 21(9):950-8. PubMed ID: 22731764
[TBL] [Abstract][Full Text] [Related]
23. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
Farias AJ; Du XL
J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
[TBL] [Abstract][Full Text] [Related]
24. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care.
Freedman RA; Virgo KS; He Y; Pavluck AL; Winer EP; Ward EM; Keating NL
Cancer; 2011 Jan; 117(1):180-9. PubMed ID: 20939011
[TBL] [Abstract][Full Text] [Related]
25. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy.
Biggers A; Shi Y; Charlson J; Smith EC; Smallwood AJ; Nattinger AB; Laud PW; Neuner JM
J Clin Oncol; 2016 Dec; 34(36):4398-4404. PubMed ID: 27998232
[TBL] [Abstract][Full Text] [Related]
26. Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
Collin LJ; Jones J; Nash R; Switchenko JM; Ward KC; McCullough LE
Breast Cancer Res Treat; 2024 Jun; 205(3):609-618. PubMed ID: 38517602
[TBL] [Abstract][Full Text] [Related]
27. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer.
Black DM; Jiang J; Kuerer HM; Buchholz TA; Smith BD
JAMA Surg; 2014 Aug; 149(8):788-96. PubMed ID: 25073831
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample.
Griggs JJ; Hawley ST; Graff JJ; Hamilton AS; Jagsi R; Janz NK; Mujahid MS; Friese CR; Salem B; Abrahamse PH; Katz SJ
J Clin Oncol; 2012 Sep; 30(25):3058-64. PubMed ID: 22869890
[TBL] [Abstract][Full Text] [Related]
29. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer.
Nurgalieva ZZ; Franzini L; Morgan RO; Vernon SW; Liu CC; Du XL
Med Oncol; 2013 Mar; 30(1):419. PubMed ID: 23292872
[TBL] [Abstract][Full Text] [Related]
30. Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand?
Seneviratne S; Campbell I; Scott N; Kuper-Hommel M; Kim B; Pillai A; Lawrenson R
Breast; 2015 Feb; 24(1):62-7. PubMed ID: 25486877
[TBL] [Abstract][Full Text] [Related]
31. Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women.
Bedi JS; Mayo RM; Truong K; Chen L; Dickes L; Sherrill WW; Jones K
Breast Cancer Res Treat; 2018 Oct; 171(3):759-765. PubMed ID: 29971626
[TBL] [Abstract][Full Text] [Related]
32. Race as an independent risk factor for breast cancer survival: breast cancer outcomes from the medical college of georgia tumor registry.
Barcenas CH; Wells J; Chong D; French J; Looney SW; Samuel TA
Clin Breast Cancer; 2010 Feb; 10(1):59-63. PubMed ID: 20133260
[TBL] [Abstract][Full Text] [Related]
33. Social Determinants of Racial Disparities in Breast Cancer Mortality Among Black and White Women.
Babatunde OA; Eberth JM; Felder T; Moran R; Truman S; Hebert JR; Zhang J; Adams SA
J Racial Ethn Health Disparities; 2021 Feb; 8(1):147-156. PubMed ID: 32385849
[TBL] [Abstract][Full Text] [Related]
34. Endocrine Therapy Nonadherence and Discontinuation in Black and White Women.
Wheeler SB; Spencer J; Pinheiro LC; Murphy CC; Earp JA; Carey L; Olshan A; Tse CK; Bell ME; Weinberger M; Reeder-Hayes KE
J Natl Cancer Inst; 2019 May; 111(5):498-508. PubMed ID: 30239824
[TBL] [Abstract][Full Text] [Related]
35. Racial disparities in all-cause mortality among younger commercially insured women with incident metastatic breast cancer.
Leopold C; Wagner AK; Zhang F; Lu CY; Earle C; Nekhlyudov L; Ross-Degnan D; Wharam JF
Breast Cancer Res Treat; 2016 Jul; 158(2):333-40. PubMed ID: 27342456
[TBL] [Abstract][Full Text] [Related]
36. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
37. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
38. Black Medicaid beneficiaries experience breast cancer treatment delays more frequently than whites.
Balasubramanian BA; Demissie K; Crabtree BF; Strickland PA; Pawlish K; Rhoads GG
Ethn Dis; 2012; 22(3):288-94. PubMed ID: 22870571
[TBL] [Abstract][Full Text] [Related]
39. Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention.
Short LJ; Fisher MD; Wahl PM; Kelly MB; Lawless GD; White S; Rodriguez NA; Willey VJ; Brawley OW
Cancer; 2010 Jan; 116(1):193-202. PubMed ID: 19877115
[TBL] [Abstract][Full Text] [Related]
40. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
